DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, ANDRZEJ FRYCZ-MODRZEWSKI CRAKOW UNIVERSITY, CRAKOW, POLAND.
DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, J. DIETL HOSPITAL, CRACOW, POLAND.
Pol Merkur Lekarski. 2024;52(3):363-367. doi: 10.36740/Merkur202403114.
Pityriasis Rubra Pilaris is a rare, chronic inflammatory dermatosis of unknown etiology, presenting with erythema and papular eruptions. Treatment is difficult due to the lack of causal therapy, guidelines and requires an individualized approach. The most common treatments are systemic retinoids, immunosuppressants, phototherapy and biological therapy. This article presents the case of a 73-year-old man suffering from type 1 pityriasis rubra pilaris. The patient was initially treated with acitretin, which was discontinued due to hypogammaglobulinemia. This rare side effect of acitretin has not been previously published. As a second-line treatment, the patient received methotrexate, but with no clinical improvement after 3 months and an increase in skin pruritus. Finally, the use of isotretinoin resulted in significant clinical improvement and was well tolerated.
红皮病性银屑病是一种罕见的、病因不明的慢性炎症性皮肤病,表现为红斑和丘疹性皮疹。由于缺乏病因治疗、指南,并且需要个体化治疗,因此治疗具有一定难度。最常见的治疗方法是系统用维 A 酸类、免疫抑制剂、光疗和生物制剂。本文介绍了 1 例 73 岁男性 1 型红皮病性银屑病患者。患者最初接受阿维 A 治疗,但由于低丙种球蛋白血症而停药。阿维 A 罕见的副作用此前尚未发表。作为二线治疗,患者接受了甲氨蝶呤治疗,但在 3 个月后没有临床改善,皮肤瘙痒反而加重。最后,使用异维 A 酸治疗后患者的临床症状明显改善,且耐受良好。